The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease.

Publisher: Elsevier Sequoia Country of Publication: Ireland NLM ID: 7903310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7573 (Electronic) Linking ISSN: 03788741 NLM ISO Abbreviation: J Ethnopharmacol Subsets: MEDLINE

Publication: Limerick : Elsevier Sequoia
Original Publication: Lausanne, Elsevier Sequoia.

Diabetes Mellitus*/drug therapy ; Diabetic Nephropathies*/drug therapy ; Drugs, Chinese Herbal*/pharmacology ; Drugs, Chinese Herbal*/therapeutic use; Animals ; Cholesterol, LDL ; Collagen ; Female ; Humans ; Inflammation/drug therapy ; Interleukin-17 ; Kidney ; Male ; Medicine, Chinese Traditional ; Mice ; NF-kappa B ; Proteinuria/drug therapy

Ethnopharmacological Relevance: Fufang Zhenzhu Tiaozhi capsule (FTZ) is a patented preparation of Chinese herbal medicine that has been used to treat hyperlipidemia, nonalcoholic fatty liver disease, atherosclerosis, and other glucolipid metabolic diseases (GLMDs) in the clinic for almost 10 years. However, how FTZ reduces albuminuria and attenuates diabetic kidney disease (DKD) progression is unknown.
Aim of the Study: To clarify the effects of FTZ on DKD mice model and to explore the underlying mechanisms.
Materials and Methods: We used streptozotocin (STZ) (40 mg/kg/d, i.p. for 5 days, consecutively) combined with a high-fat diet (HFD) to induce a DKD mouse model, followed by FTZ (1, 2 g/kg/d, i.g.) treatment for 12 weeks. Losartan (30 mg/kg/d, i.g.) was used as a positive control. Measurements of 24 h proteinuria, serum creatinine (SCr), fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) levels and expression levels of fibronectin (FN), collagen IV, inflammatory cytokines, inflammatory cells, interleukin-17A (IL-17A) and the nuclear transcription factor-κB (NF-κB) signaling pathway in the kidney were examined.
Results: FTZ effectively decreased 24 h proteinuria, Scr, FBG, TC, TG, and LDL-C levels, inhibited mesangial cell expansion, reduced FN and collagen IV accumulation, and F4/80 ⁺ macrophage cell infiltration and Ly-6G ⁺ neutrophil infiltration in glomerulus and tubulointerstitium. Furthermore, IL-17A production and the NF-κB signaling pathway were also downregulated after the administration of FTZ.
Conclusion: FTZ might attenuate DKD progression, and inhibited kidney inflammation and fibrosis by inhibiting the expression of RORγT and IL-17A in vivo, offering novel insights for the clinical application of FTZ.
(Copyright © 2022 Elsevier B.V. All rights reserved.)

Keywords: Chinese medicine; Diabetic kidney disease; Inflammation

0 (Cholesterol, LDL)
0 (Drugs, Chinese Herbal)
0 (Interleukin-17)
0 (NF-kappa B)
9007-34-5 (Collagen)

Date Created: 20220305 Date Completed: 20220419 Latest Revision: 20220419

20240105

10.1016/j.jep.2022.115165

35247475